Bluejay Diagnostics Inc Financials
This page shows Bluejay Diagnostics Inc (BJDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Bluejay Diagnostics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Bluejay Diagnostics Inc generates $1.01 in operating cash flow (-$7.8M OCF vs -$7.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Bluejay Diagnostics Inc earns $-8.7 in operating income for every $1 of interest expense (-$7.2M vs $823K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Bluejay Diagnostics Inc's EBITDA was -$7.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26.6% from the prior year.
Bluejay Diagnostics Inc generated -$8.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 9.9% from the prior year.
Bluejay Diagnostics Inc reported -$7.7M in net income in fiscal year 2024. This represents an increase of 22.5% from the prior year.
Bluejay Diagnostics Inc earned $-114.19 per diluted share (EPS) in fiscal year 2024. This represents an increase of 96.9% from the prior year.
Bluejay Diagnostics Inc held $4.3M in cash against $0 in long-term debt as of fiscal year 2024.
Bluejay Diagnostics Inc had 554,012 shares outstanding in fiscal year 2024. This represents an increase of 17782.9% from the prior year.
Bluejay Diagnostics Inc invested $3.5M in research and development in fiscal year 2024. This represents a decrease of 39.2% from the prior year.
Bluejay Diagnostics Inc invested $307K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 56.4% from the prior year.
BJDX Income Statement
| Metric | Q3'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 | Q2'23 | Q4'21 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $249K | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $200K | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | $49K | N/A | N/A |
| R&D Expenses | $786K | N/A | $1.4M | N/A | $1.4M+82.4% | $756K | N/A | $443K |
| SG&A Expenses | $831K | N/A | -$20K | N/A | $146K-87.8% | $1.2M | N/A | $445K |
| Operating Income | -$1.6M | N/A | -$2.3M | N/A | -$2.8M-41.5% | -$2.0M | N/A | -$958K |
| Interest Expense | $200 | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.6M | N/A | -$2.3M | N/A | -$3.0M-52.8% | -$1.9M | N/A | -$1.2M |
| EPS (Diluted) | $-1.01 | N/A | $-16.67 | N/A | $-2.94-47.0% | $-2.00 | N/A | $-0.11 |
BJDX Balance Sheet
| Metric | Q3'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 | Q2'23 | Q4'21 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.9M+0.4% | $4.9M-41.0% | $8.2M-39.0% | $13.5M-13.9% | $15.7M-13.1% | $18.1M-14.0% | $21.0M+480.2% | $3.6M |
| Current Assets | $3.4M+4.1% | $3.2M-50.7% | $6.5M-44.6% | $11.8M-15.4% | $13.9M-18.3% | $17.1M-17.5% | $20.7M+533.0% | $3.3M |
| Cash & Equivalents | $3.1M+39.6% | $2.2M-56.5% | $5.1M-49.8% | $10.1M-23.9% | $13.3M-13.4% | $15.3M-19.5% | $19.0M+717.5% | $2.3M |
| Inventory | N/A | N/A | N/A | N/A | $893K+33.1% | $671K | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.2M-39.3% | $2.0M-34.9% | $3.0M+53.2% | $2.0M+4.5% | $1.9M+34.4% | $1.4M+121.2% | $637K-86.5% | $4.7M |
| Current Liabilities | $1.1M-35.1% | $1.8M-36.7% | $2.8M+70.7% | $1.6M+7.7% | $1.5M+55.4% | $980K+53.7% | $637K | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.7M+27.6% | $2.9M-44.5% | $5.2M-54.8% | $11.5M-16.4% | $13.8M-17.1% | $16.7M-18.3% | $20.4M+1985.6% | -$1.1M |
| Retained Earnings | -$40.1M-48.7% | -$27.0M-9.3% | -$24.6M-45.0% | -$17.0M-16.3% | -$14.6M-25.4% | -$11.7M-51.4% | -$7.7M-23.4% | -$6.2M |
BJDX Cash Flow Statement
| Metric | Q3'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 | Q2'23 | Q4'21 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.4M+51.0% | -$2.8M-146.9% | -$1.1M+61.8% | -$2.9M-133.5% | -$1.3M+24.0% | -$1.7M+34.2% | -$2.5M-126.3% | -$1.1M |
| Capital Expenditures | $1K-98.7% | $88K+18.0% | $74K-68.7% | $238K-69.9% | $791K+542.1% | $123K+595.0% | $18K+314.3% | $4K |
| Free Cash Flow | -$1.5M+49.3% | -$2.9M-138.9% | -$1.2M+62.3% | -$3.2M-55.1% | -$2.1M-15.2% | -$1.8M+29.9% | -$2.5M-127.0% | -$1.1M |
| Investing Cash Flow | -$1K+98.7% | -$88K-18.0% | -$74K+68.7% | -$238K+69.9% | -$791K-542.1% | -$123K-595.0% | -$18K-314.3% | -$4K |
| Financing Cash Flow | -$1K+66.7% | -$3K-100.3% | $1.2M | N/A | N/A | N/A | $19.3M+1736.1% | $1.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | $1K | N/A | N/A | N/A | N/A | N/A |
BJDX Financial Ratios
| Metric | Q3'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 | Q2'23 | Q4'21 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 19.6% | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -797.3% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -777.9% | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 518.5% |
| Return on Assets | -32.7% | N/A | -27.9% | N/A | -18.9%-8.1pp | -10.7% | N/A | -32.9% |
| Current Ratio | 2.92+1.1 | 1.82-0.5 | 2.33-4.9 | 7.19-2.0 | 9.15-8.3 | 17.41-15.0 | 32.43 | N/A |
| Debt-to-Equity | 0.32-0.4 | 0.68+0.1 | 0.58+0.4 | 0.17+0.0 | 0.14+0.1 | 0.08+0.1 | 0.03+4.4 | -4.35 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -715.7% | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Bluejay Diagnostics Inc profitable?
No, Bluejay Diagnostics Inc (BJDX) reported a net income of -$7.7M in fiscal year 2024.
What is Bluejay Diagnostics Inc's earnings per share (EPS)?
Bluejay Diagnostics Inc (BJDX) reported diluted earnings per share of $-114.19 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Bluejay Diagnostics Inc's EBITDA?
Bluejay Diagnostics Inc (BJDX) had EBITDA of -$7.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bluejay Diagnostics Inc's free cash flow?
Bluejay Diagnostics Inc (BJDX) generated -$8.1M in free cash flow during fiscal year 2024. This represents a 9.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bluejay Diagnostics Inc's operating cash flow?
Bluejay Diagnostics Inc (BJDX) generated -$7.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Bluejay Diagnostics Inc's total assets?
Bluejay Diagnostics Inc (BJDX) had $6.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Bluejay Diagnostics Inc's capital expenditures?
Bluejay Diagnostics Inc (BJDX) invested $307K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Bluejay Diagnostics Inc spend on research and development?
Bluejay Diagnostics Inc (BJDX) invested $3.5M in research and development during fiscal year 2024.
How many shares does Bluejay Diagnostics Inc have outstanding?
Bluejay Diagnostics Inc (BJDX) had 554,012 shares outstanding as of fiscal year 2024.
What is Bluejay Diagnostics Inc's current ratio?
Bluejay Diagnostics Inc (BJDX) had a current ratio of 6.05 as of fiscal year 2024, which is generally considered healthy.
What is Bluejay Diagnostics Inc's debt-to-equity ratio?
Bluejay Diagnostics Inc (BJDX) had a debt-to-equity ratio of 0.16 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bluejay Diagnostics Inc's return on assets (ROA)?
Bluejay Diagnostics Inc (BJDX) had a return on assets of -115.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Bluejay Diagnostics Inc's cash runway?
Based on fiscal year 2024 data, Bluejay Diagnostics Inc (BJDX) had $4.3M in cash against an annual operating cash burn of $7.8M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Bluejay Diagnostics Inc's Piotroski F-Score?
Bluejay Diagnostics Inc (BJDX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bluejay Diagnostics Inc's earnings high quality?
Bluejay Diagnostics Inc (BJDX) has an earnings quality ratio of 1.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bluejay Diagnostics Inc cover its interest payments?
Bluejay Diagnostics Inc (BJDX) has an interest coverage ratio of -8.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.